Key Points
-
Cytosine-5 DNA methylation occurs in mammals at CpG dinucleotides. About 70% of the CpG dinucleotides in the mammalian genome are methylated.
-
The complexity of varying distributions of methylated cytosines across the approximately 50 million CpG dinucleotides of each mammalian genome in a DNA sample that is derived from a heterogenous tissue sample is a diagnostic dream and an analytical nightmare.
-
A nomenclature for the three principal approaches to methylation analysis — methylation content, methylation levels and methylation patterns — is proposed. The latter two types of analysis can be performed at multiple sites in the genome to yield methylation profiles.
-
In the past decade, DNA methylation analysis has been revolutionized by two technological advances — bisulphite modification of DNA and methylation-specific polymerase chain reaction (MSP).
-
CpG islands are approximately 1-kb stretches of DNA-containing clusters of CpG dinucleotides that are usually unmethylated in normal cells and are often located near the 5′ ends of genes. Methylation of promoter CpG islands is associated with a closed chromatin structure and transcriptional silencing of the associated gene.
-
Hypermethylation of CpG islands is a common event in carcinogenesis. The transcriptional silencing of tumour-suppressor genes by promoter CpG island hypermethylation can contribute to oncogenesis.
-
DNA methylation profiles represent a more chemically and biologically stable source of molecular diagnostic information than RNA or most proteins. The diagnostic potential of DNA methylation profiles is still largely untapped.
-
Cancer-specific DNA methylation patterns can be detected in tumour-derived free DNA in the bloodstream and in epithelial tumour cells shed into the lumen, offering a promising approach to the early detection of cancer. Clinical application will first require further validation and will ultimately be based on standardized MSP-based technologies, such as MethyLight, rather than on gel-based techniques.
-
A distinction between the clinical and analytical sensitivities of DNA methylation biomarkers is proposed.
Abstract
The past few years have seen an explosion of interest in the epigenetics of cancer. This has been a consequence of both the exciting coalescence of the chromatin and DNA methylation fields, and the realization that DNA methylation changes are involved in human malignancies. The ubiquity of DNA methylation changes has opened the way to a host of innovative diagnostic and therapeutic strategies. Recent advances attest to the great promise of DNA methylation markers as powerful future tools in the clinic.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Robertson, K. D. & Wolffe, A. P. DNA methylation in health and disease. Nature Rev. Genet. 1, 11–19 (2000).
Ordway, J. M. & Curran, T. Methylation matters: modeling a manageable genome. Cell Growth Differ. 13, 149–162 (2002).
Li, E. Chromatin modification and epigenetic reprogramming in mammalian development. Nature Rev. Genet. 3, 662–673 (2002).
Li, E., Bestor, T. H. & Jaenisch, R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69, 915–926 (1992).
Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 16, 6–21 (2002).
Walsh, C. P., Chaillet, J. R. & Bestor, T. H. Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nature Genet. 20, 116–117 (1998). Provides experimental support for the importance of DNA methylation in the protection against intragenomic parasites in vertebrate genomes.
Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nature Rev. Genet. 3, 415–428 (2002). An excellent overview of the field of gene silencing by aberrant promoter CpG island hypermethylation in cancer.
Ramsahoye, B. H. et al. Non-CpG methylation is prevalent in embryonic stem cells and may be mediated by DNA methyltransferase 3a. Proc. Natl Acad. Sci. USA 97, 5237–5242 (2000).
Chan, M. F. et al. Reduced rates of gene loss, gene silencing, and gene mutation in DNMT1-deficient embryonic stem cells. Mol. Cell. Biol. 21, 7587–7600 (2001).
Sved, J. & Bird, A. The expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model. Proc. Natl Acad. Sci. USA 87, 4692–4696 (1990).
Issa, J. P. et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nature Genet. 7, 536–540 (1994).
Ahuja, N., Li, Q., Mohan, A. L., Baylin, S. B. & Issa, J. P. Aging and DNA methylation in colorectal mucosa and cancer. Cancer Res. 58, 5489–5494 (1998). References 11 and 12 reported the age-related hypermethylation of CpG islands in histologically normal tissues.
Futscher, B. W. et al. Role for DNA methylation in the control of cell type specific maspin expression. Nature Genet. 31, 175–179 (2002). Shows that methylation of CpG islands can be important in the establishment and maintenance of cell-type-restricted gene expression.
Strichman-Almashanu, L. Z. et al. A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes. Genome Res. 12, 543–554 (2002).
Yoder, J. A., Walsh, C. P. & Bestor, T. H. Cytosine methylation and the ecology of intragenomic parasites. Trends Genet. 13, 335–340 (1997).
Hoal-van Helden, E. G. & van Helden, P. D. Age-related methylation changes in DNA may reflect the proliferative potential of organs. Mutat. Res. 219, 263–266 (1989).
Feinberg, A. P. & Vogelstein, B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89–92 (1983). The first to describe DNA hypomethylation of single genes in human tumour DNA.
Gama-Sosa, M. A. et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11, 6883–6894 (1983). The first to describe genome-wide DNA hypomethylation in human tumour DNA.
Jones, P. A. & Laird, P. W. Cancer epigenetics comes of age. Nature Genet. 21, 163–167 (1999).
Rampersaud, G. C., Kauwell, G. P., Hutson, A. D., Cerda, J. J. & Bailey, L. B. Genomic DNA methylation decreases in response to moderate folate depletion in elderly women. Am. J. Clin. Nutr. 72, 998–1003 (2000).
Kim, Y. I. et al. Effects of folate supplementation on two provisional molecular markers of colon cancer: a prospective, randomized trial. Am. J. Gastroenterol. 96, 184–195 (2001).
Cravo, M. L. et al. Effect of folate supplementation on DNA methylation of rectal mucosa in patients with colonic adenomas: correlation with nutrient intake. Clin. Nutr. 17, 45–49 (1998).
Friso, S. et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status. Proc. Natl Acad. Sci. USA 99, 5606–5611 (2002).
Paz, M. F. et al. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res. 62, 4519–4524 (2002).
Esteller, M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21, 5427–5440 (2002).
Plass, C. Cancer epigenomics. Hum. Mol. Genet. 11, 2479–2488 (2002).
Di Croce, L. et al. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295, 1079–1082 (2002). The first paper to report the targeted recruitment of a DNA methyltransferase in the hypermethylation of a CpG island.
Velicescu, M. et al. Cell division is required for de novo methylation of CpG islands in bladder cancer cells. Cancer Res. 62, 2378–2384 (2002).
Song, J. Z., Stirzaker, C., Harrison, J., Melki, J. R. & Clark, S. J. Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 21, 1048–1061 (2002).
Karpf, A. R. & Jones, D. A. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21, 5496–5503 (2002).
Siegmund, K. D. & Laird, P. W. Analysis of complex methylation data. Methods 27, 170–178 (2002).
Frommer, M. et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl Acad. Sci. USA 89, 1827–1831 (1992). Revolutionized the field of DNA methylation analysis by introducing the sodium bisulphite conversion technique.
Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D. & Baylin, S. B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93, 9821–9826 (1996). Introduced a technique that made DNA methylation analysis in human tumours widely accessible.
Costello, J. F. et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nature Genet. 24, 132–138 (2000). This paper made the first convincing case for the wide extent of DNA methylation changes in human tumours.
Adorjan, P. et al. Tumour class prediction and discovery by microarray-based DNA methylation analysis. Nucleic Acids Res. 30, E21 (2002).
Yan, P. S. et al. Applications of CpG island microarrays for high-throughput analysis of DNA methylation. J. Nutr. 132, 2430S–2434S (2002).
Eads, C. A. et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res. 61, 3410–3418 (2001).
Esteller, M., Corn, P. G., Baylin, S. B. & Herman, J. G. A gene hypermethylation profile of human cancer. Cancer Res. 61, 3225–3229 (2001).
Virmani, A. K. et al. Hierarchical clustering of lung cancer cell lines using DNA methylation markers. Cancer Epidemiol. Biomarkers Prev. 11, 291–297 (2002).
Singal, R. & Grimes, S. R. Microsoft Word macro for analysis of cytosine methylation by the bisulfite deamination reaction. Biotechniques 30, 116–120 (2001).
Anbazhagan, R., Herman, J. G., Enika, K. & Gabrielson, E. Spreadsheet-based program for the analysis of DNA methylation. Biotechniques 30, 110–114 (2001).
Li, L. C. & Dahiya, R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 18, 1427–1431 (2002).
Rand, K., Qu, W., Ho, T., Clark, S. J. & Molloy, P. Conversion-specific detection of DNA methylation using real-time polymerase chain reaction (ConLight-MSP) to avoid false positives. Methods 27, 114–120 (2002).
Xiong, Z. & Laird, P. W. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25, 2532–2534 (1997).
Gonzalgo, M. L. & Jones, P. A. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res. 25, 2529–2531 (1997).
Takai, D. & Jones, P. A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc. Natl Acad. Sci. USA 99, 3740–3745 (2002).
Cui, H., Horon, I. L., Ohlsson, R., Hamilton, S. R. & Feinberg, A. P. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nature Med. 4, 1276–1280 (1998). Provides the first indication that loss of imprinting might represent a systemic defect that is present even in haematopoietic cells of individuals with colorectal cancer.
Laird, P. W. Oncogenic mechanisms mediated by DNA methylation. Mol. Med. Today 3, 223–229 (1997).
Sullivan Pepe, M. et al. Phases of biomarker development for early detection of cancer. J. Natl Cancer Inst. 93, 1054–1061 (2001). The first paper to provide a systematic approach to biomarker development for the early detection of cancer.
Lee, W. H. et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc. Natl Acad. Sci. USA 91, 11733–11737 (1994).
Jeronimo, C. et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J. Natl Cancer Inst. 93, 1747–1752 (2001).
Kawakami, K. et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl Cancer Inst. 92, 1805–1811 (2000).
Eads, C. A. et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 60, 5021–5026 (2000).
Eads, C. A. et al. MethyLight: a high–throughput assay to measure DNA methylation. Nucleic Acids Res. 28, E32 (2000).
Eads, C. A. et al. CpG island hypermethylation in human colorectal tumors is not associated with DNA methyltransferase overexpression. Cancer Res. 59, 2302–2306 (1999).
Lo, Y. M. et al. Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res. 59, 3899–3903 (1999).
Sidransky, D. Emerging molecular markers of cancer. Nature Rev. Cancer 2, 210–219 (2002).
Leon, S. A., Shapiro, B., Sklaroff, D. M. & Yaros, M. J. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 37, 646–650 (1977). The first to describe the presence of increased levels of free DNA in the serum of cancer patients.
Vasioukhin, V. et al. Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br. J. Haematol. 86, 774–779 (1994). Provided the first proof that the free DNA in serum was of tumour origin.
Jahr, S. et al. DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res. 61, 1659–1665 (2001).
Silva, J. M. et al. Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. 59, 3251–3256 (1999).
Goessl, C. et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res. 60, 5941–5945 (2000).
Grady, W. M., Rajput, A., Lutterbaugh, J. D. & Markowitz, S. D. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61, 900–902 (2001).
Dominguez, G. et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin. Cancer Res. 8, 980–985 (2002).
Zou, H. Z. et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. 8, 188–191 (2002).
Wong, I. H. et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res. 59, 71–73 (1999).
Esteller, M. et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59, 67–70 (1999).
Sanchez-Cespedes, M. et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 60, 892–895 (2000).
Nakayama, H. et al. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett. 188, 115–119 (2002).
Lee, T. L. et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin. Cancer Res. 8, 1761–1766 (2002).
Wong, T. S. et al. High frequency of promoter hypermethylation of the death-associated protein-kinase gene in nasopharyngeal carcinoma and its detection in the peripheral blood of patients. Clin. Cancer Res. 8, 433–437 (2002).
An, Q. et al. Detection of p16 hypermethylation in circulating plasma DNA of non-small cell lung cancer patients. Cancer Lett. 188, 109–114 (2002).
Lecomte, T. et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int. J. Cancer 100, 542–548 (2002).
Palmisano, W. A. et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 60, 5954–5958 (2000).
Hanley, J. A. & McNeil, B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29–36 (1982).
Jeronimo, C. et al. Quantitative GSTP1 hypermethylation in bodily fluids of patients with prostate cancer. Urology 60, 1131–1135 (2002).
Nakagawa, H. et al. Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res. 61, 6991–6995 (2001).
van de Vijver, M. J. et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347, 1999–2009 (2002).
Pullarkat, S. T. et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1, 65–70 (2001).
Hayes, D. F., Trock, B. & Harris, A. L. Assessing the clinical impact of prognostic factors: when is 'statistically significant' clinically useful? Breast Cancer Res. Treat. 52, 305–319 (1998).
Silva, J. M. et al. Persistence of tumor DNA in plasma of breast cancer patients after mastectomy. Ann. Surg. Oncol. 9, 71–76 (2002).
Wei, S. H. et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res. 8, 2246–2252 (2002).
Tada, Y. et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res. 62, 4048–4053 (2002).
Powell, M. A. et al. Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer 94, 2941–2952 (2002).
Maruyama, R. et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin. Cancer Res. 8, 514–519 (2002).
Maruyama, R. et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res. 61, 8659–8663 (2001).
Widschwendter, M. & Jones, P. A. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Clin. Cancer Res. 8, 17–21 (2002). Commentary re: Kwong, J. et al. Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res. 8, 131–137 (2002), and Zou, H. -Z. et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. 8, 188–191 (2002).
Brabender, J. et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 20, 3528–3532 (2001).
Usadel, H. et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62, 371–375 (2002).
Ogi, K. et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin. Cancer Res. 8, 3164–3171 (2002).
Garcia-Manero, G. et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin. Cancer Res. 8, 2217–2224 (2002).
Tang, X. et al. Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer. J. Natl Cancer Inst. 92, 1511–1516 (2000).
Brabender, J. et al. Quantitative O(6)-methylguanine DNA methyltransferase methylation analysis in curatively resected non-small cell lung cancer: associations with clinical outcome. Clin. Cancer Res. 9, 223–227 (2003).
Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350–1354 (2000).
Esteller, M. et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J. Natl Cancer Inst. 94, 26–32 (2002).
Buckner, J. C. & Moynihan, T. J. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 344, 686–688 (2001).
Quinn, D. I. The DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 344, 686–688 (2001).
Novik, K. L. et al. Epigenomics: genome-wide study of methylation phenomena. Curr. Issues Mol. Biol. 4, 111–128 (2002).
Huang, T. H., Perry, M. R. & Laux, D. E. Methylation profiling of CpG islands in human breast cancer cells. Hum. Mol. Genet. 8, 459–470 (1999).
Toyota, M. et al. Methylation profiling in acute myeloid leukemia. Blood 97, 2823–2829 (2001).
Toyota, M. et al. CpG island methylator phenotype in colorectal cancer. Proc. Natl Acad. Sci. USA 96, 8681–8686 (1999).
Liang, G. et al. DNA methylation differences associated with tumor tissues identified by genome scanning analysis. Genomics 53, 260–268 (1998).
Li, J. et al. NotI subtraction and NotI-specific microarrays to detect copy number and methylation changes in whole genomes. Proc. Natl Acad. Sci. USA 99, 10724–10729 (2002).
Hatada, I. et al. A microarray-based method for detecting methylated loci. J. Hum. Genet. 47, 448–451 (2002).
Balog, R. P. et al. Parallel assessment of CpG methylation by two-color hybridization with oligonucleotide arrays. Anal. Biochem. 309, 301–310 (2002).
Shi, H. et al. Oligonucleotide-based microarray for DNA methylation analysis: principles and applications. J. Cell Biochem. 88, 138–143 (2003).
Model, F., Adorjan, P., Olek, A. & Piepenbrock, C. Feature selection for DNA methylation based cancer classification. Bioinformatics 17, S157–S164 (2001).
Miller, O. J., Schnedl, W., Allen, J. & Erlanger, B. F. 5-Methylcytosine localised in mammalian constitutive heterochromatin. Nature 251, 636–637 (1974).
Sano, H., Royer, H. D. & Sager, R. Identification of 5-methylcytosine in DNA fragments immobilized on nitrocellulose paper. Proc. Natl Acad. Sci. USA 77, 3581–3585 (1980).
Kuo, K. C., McCune, R. A., Gehrke, C. W., Midgett, R. & Ehrlich, M. Quantitative reversed-phase high performance liquid chromatographic determination of major and modified deoxyribonucleosides in DNA. Nucleic Acids Res. 8, 4763–4776 (1980).
Wilson, V. L. et al. Genomic 5-methylcytosine determination by 32P-postlabeling analysis. Anal. Biochem. 152, 275–284 (1986).
Annan, R. S., Kresbach, G. M., Giese, R. W. & Vouros, P. Trace detection of modified DNA bases via moving-belt liquid chromatography-mass spectrometry using electrophoric derivatization and negative chemical ionization. J. Chromatogr. 465, 285–296 (1989).
Balaghi, M. & Wagner, C. DNA methylation in folate deficiency: use of CpG methylase. Biochem. Biophys. Res. Commun. 193, 1184–1190 (1993).
Wu, J. et al. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc. Natl Acad. Sci. USA 90, 8891–8895 (1993).
Oakeley, E. J., Schmitt, F. & Jost, J. P. Quantification of 5-methylcytosine in DNA by the chloroacetaldehyde reaction. Biotechniques 27, 744–746 (1999).
Gowher, H., Leismann, O. & Jeltsch, A. DNA of Drosophila melanogaster contains 5-methylcytosine. EMBO J. 19, 6918–6923 (2000).
Fraga, M. F. et al. High-performance capillary electrophoretic method for the quantification of 5-methyl 2′-deoxycytidine in genomic DNA: application to plant, animal and human cancer tissues. Electrophoresis 23, 1677–1681 (2002).
Galm, O. et al. Enzymatic regional methylation assay: a novel method to quantify regional CpG methylation density. Genome Res. 12, 153–157 (2002).
Bird, A. P. & Southern, E. M. Use of restriction enzymes to study eukaryotic DNA methylation: I. The methylation pattern in ribosomal DNA from Xenopus laevis. J. Mol. Biol. 118, 27–47 (1978).
Waalwijk, C. & Flavell, R. A. DNA methylation at a CCGG sequence in the large intron of the rabbit beta-globin gene: tissue-specific variations. Nucleic Acids Res. 5, 4631–4634 (1978).
Pfeifer, G. P., Steigerwald, S. D., Mueller, P. R., Wold, B. & Riggs, A. D. Genomic sequencing and methylation analysis by ligation mediated PCR. Science 246, 810–813 (1989).
Singer-Sam, J., LeBon, J. M., Tanguay, R. L. & Riggs, A. D. A quantitative HpaII–PCR assay to measure methylation of DNA from a small number of cells. Nucleic Acids Res. 18, 687 (1990).
Steigerwald, S. D., Pfeifer, G. P. & Riggs, A. D. Ligation-mediated PCR improves the sensitivity of methylation analysis by restriction enzymes and detection of specific DNA strand breaks. Nucleic Acids Res. 18, 1435–1439 (1990).
Heiskanen, M., Syvanen, A. C., Siitari, H., Laine, S. & Palotie, A. A novel method to quantitate methylation of specific genomic regions. PCR Methods Appl. 4, 26–30 (1994).
Liang, G. et al. Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive elements. Mol. Cell. Biol. 22, 480–491 (2002).
Matin, M. M., Baumer, A. & Hornby, D. P. An analytical method for the detection of methylation differences at specific chromosomal loci using primer extension and ion pair reverse phase HPLC. Hum. Mutat. 20, 305–311 (2002).
Akey, D., Akey, J., Zhang, K. & Jin, L. Assaying DNA methylation based on high-throughput melting curve approaches. Genomics 80, 376 (2002).
Uhlmann, K., Brinckmann, A., Toliat, M. R., Ritter, H. & Nurnberg, P. Evaluation of a potential epigenetic biomarker by quantitative methyl- single nucleotide polymorphism analysis. Electrophoresis 23, 4072–4079 (2002).
Ohmori, H., Tomizawa, J. I. & Maxam, A. M. Detection of 5-methylcytosine in DNA sequences. Nucleic Acids Res. 5, 1479–1485 (1978).
Fritzsche, E., Hayatsu, H., Igloi, G. L., Iida, S. & Kossel, H. The use of permanganate as a sequencing reagent for identification of 5-methylcytosine residues in DNA. Nucleic Acids Res. 15, 5517–5528 (1987).
Collins, M. & Myers, R. M. Alterations in DNA helix stability due to base modifications can be evaluated using denaturing gradient gel electrophoresis. J. Mol. Biol. 198, 737–744 (1987).
Uhlmann, K., Marczinek, K., Hampe, J., Thiel, G. & Nurnberg, P. Changes in methylation patterns identified by two-dimensional DNA fingerprinting. Electrophoresis 20, 1748–1755 (1999).
Aggerholm, A., Guldberg, P., Hokland, M. & Hokland, P. Extensive intra- and interindividual heterogeneity of p15INK4B methylation in acute myeloid leukemia. Cancer Res. 59, 436–441 (1999).
Nuovo, G. J., Plaia, T. W., Belinsky, S. A., Baylin, S. B. & Herman, J. G. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis. Proc. Natl Acad. Sci. USA 96, 12754–12759 (1999).
Burri, N. & Chaubert, P. Complex methylation patterns analyzed by single-strand conformation polymorphism. Biotechniques 26, 232–234 (1999).
Bianco, T., Hussey, D. & Dobrovic, A. Methylation-sensitive, single-strand conformation analysis (MS-SSCA): a rapid method to screen for and analyze methylation. Hum. Mutat. 14, 289–293 (1999).
Maekawa, M. et al. DNA methylation analysis using bisulfite treatment and PCR-single-strand conformation polymorphism in colorectal cancer showing microsatellite instability. Biochem. Biophys. Res. Commun. 262, 671–676 (1999).
Baumer, A., Wiedemann, U., Hergersberg, M. & Schinzel, A. A novel MSP/DHPLC method for the investigation of the methylation status of imprinted genes enables the molecular detection of low cell mosaicisms. Hum. Mutat. 17, 423–430 (2001).
Worm, J., Aggerholm, A. & Guldberg, P. In-tube DNA methylation profiling by fluorescence melting curve analysis. Clin. Chem. 47, 1183–1189 (2001).
Cottrell, S. E. & Laird, P. W. Sensitive detection of DNA methylation. Ann. NY Acad. Sci. (in the press).
Kawai, J. et al. Methylation profiles of genomic DNA of mouse developmental brain detected by restriction landmark genomic scanning (RLGS) method. Nucleic Acids Res. 21, 5604–5608 (1993).
Cross, S. H., Charlton, J. A., Nan, X. & Bird, A. P. Purification of CpG islands using a methylated DNA binding column. Nature Genet. 6, 236–244 (1994).
Gonzalgo, M. L. et al. Identification and characterization of differentially methylated regions of genomic DNA by methylation-sensitive arbitrarily primed PCR. Cancer Res. 57, 594–599 (1997).
Toyota, M. et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 59, 2307–2312 (1999).
Brock, G. J., Huang, T. H., Chen, C. M. & Johnson, K. J. A novel technique for the identification of CpG islands exhibiting altered methylation patterns (ICEAMP). Nucleic Acids Res. 29, E123 (2001).
Gitan, R. S., Shi, H., Chen, C. M., Yan, P. S. & Huang, T. H. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res. 12, 158–164 (2002).
Frigola, J., Ribas, M., Risques, R. A. & Peinado, M. A. Methylome profiling of cancer cells by amplification of inter-methylated sites (AIMS). Nucleic Acids Res. 30, E28 (2002).
Suzuki, H. et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nature Genet. 31, 141–149 (2002).
Liang, G., Gonzales, F. A., Jones, P. A., Orntoft, T. F. & Thykjaer, T. Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2′-deoxycytidine. Cancer Res. 62, 961–966 (2002).
Tompa, R. et al. Genome-wide profiling of DNA methylation reveals transposon targets of CHROMOMETHYLASE3. Curr. Biol. 12, 65–68 (2002).
Valenzuela, M. T. et al. Assessing the use of p16(INK4a) promoter gene methylation in serum for detection of bladder cancer. Eur. Urol. 42, 622–630 (2002).
Silva, J. M. et al. Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients. Br. J. Cancer 80, 1262–1264 (1999).
Hibi, K. et al. Molecular detection of p16 promoter methylation in the serum of patients with esophageal squamous cell carcinoma. Clin. Cancer Res. 7, 3135–3138 (2001).
Wong, I. H., Lo, Y. M., Yeo, W., Lau, W. Y. & Johnson, P. J. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin. Cancer Res. 6, 3516–3521 (2000).
Kurakawa, E. et al. Hypermethylation of p16(INK4a) and p15(INK4b) genes in non-small cell lung cancer. Int. J. Oncol. 19, 277–281 (2001).
Bearzatto, A. et al. p16(INK4A) hypermethylation detected by fluorescent methylation- specific PCR in plasmas from non-small cell lung cancer. Clin. Cancer Res. 8, 3782–3787 (2002).
Chan, M. W. et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin. Cancer Res. 8, 464–470 (2002).
Evron, E. et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 357, 1335–1336 (2001).
Rosas, S. L. et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res. 61, 939–942 (2001).
Belinsky, S. A. et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc. Natl Acad. Sci. USA 95, 11891–11896 (1998).
Ahrendt, S. A. et al. Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J. Natl Cancer Inst. 91, 332–339 (1999).
Kersting, M. et al. Differential frequencies of p16(INK4a) promoter hypermethylation, p53 mutation, and K-ras mutation in exfoliative material mark the development of lung cancer in symptomatic chronic smokers. J. Clin. Oncol. 18, 3221–3229 (2000).
Belinsky, S. A. et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res. 62, 2370–2377 (2002).
Suh, C. I. et al. Comparison of telomerase activity and GSTP1 promoter methylation in ejaculate as potential screening tests for prostate cancer. Mol. Cell Probes 14, 211–217 (2000).
Cairns, P. et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin. Cancer Res. 7, 2727–2730 (2001).
Goessl, C. et al. DNA-based detection of prostate cancer in urine after prostatic massage. Urology 58, 335–338 (2001).
Goessl, C. et al. Methylation-specific PCR for detection of neoplastic DNA in biopsy washings. J. Pathol. 196, 331–334 (2002).
Acknowledgements
I apologize to colleagues whose contributions could not be cited due to space constraints. Supported by National Institutes of Health grants. Disclosure: Peter W. Laird is shareholder and Scientific Advisory Board Member of Epigenomics, AG, which has a commercial interest in the development of DNA methylation markers for disease detection and diagnosis. None of the work performed in the laboratory of Peter W. Laird is or has been supported by Epigenomics.
Author information
Authors and Affiliations
Related links
Related links
DATABASES
Cancer.gov
LocusLink
FURTHER INFORMATION
Glossary
- GENOMIC IMPRINTING
-
Process by which genes are selectively expressed by the maternal or paternal homologue of a chromosome.
- X-INACTIVATION
-
Mammalian females have two X chromosomes per genome, whereas males have only one. In female mammals, one X chromosome is functionally silenced during embryogenesis to ensure that the stoichiometry of X-chromosomal and autosomal gene products is the same in males and females.
- CpG ISLAND
-
First described by Adrian Bird as an unmethylated HpaII tiny fragment (HTF) and formerly commonly defined as a contiguous window of DNA of at least 200 base pairs in which the G:C content is at least 50% and the ratio of observed CpG frequency over the expected frequency exceeds 0.6. Recently, a more stringent definition of a 500-base-pair window with a G:C content of at least 55% and an observed over expected CpG frequency of at least 0.65 has been proposed to exclude most Alu repeat sequences.
- DNA HYPERMETHYLATION
-
An increased level of DNA methylation in a DNA sample at either an individual CpG dinucleotide or at a group of CpG dinucleotides relative to a reference DNA sample, usually derived from a normal tissue.
- DNA HYPOMETHYLATION
-
A decreased level of DNA methylation in a DNA sample at either an individual CpG dinucleotide or at a group of CpG dinucleotides (or even the entire genome) relative to a reference DNA sample, usually derived from a normal tissue.
- POLYMORPHISM
-
A sequence variant that is present among human populations.
- BIOMARKER
-
In cancer research and detection, a biomarker refers to a substance or process that is indicative of the presence of cancer in the body. It might be either a molecule secreted by a malignancy itself, or it can be a specific response of the body to the presence of cancer.
- APC
-
(Adenomatous polyposis coli). A tumour-suppressor gene that encodes a component of the WNT–β-catenin signalling pathway that is inactivated in most colorectal adenocarcinomas.
Rights and permissions
About this article
Cite this article
Laird, P. The power and the promise of DNA methylation markers. Nat Rev Cancer 3, 253–266 (2003). https://doi.org/10.1038/nrc1045
Issue Date:
DOI: https://doi.org/10.1038/nrc1045
This article is cited by
-
Optimized screening of DNA methylation sites combined with gene expression analysis to identify diagnostic markers of colorectal cancer
BMC Cancer (2023)
-
Liquid biopsies: the future of cancer early detection
Journal of Translational Medicine (2023)
-
DNA methylation as a potential mediator of the association between indoor air pollution and neurodevelopmental delay in a South African birth cohort
Clinical Epigenetics (2023)
-
Low-dose arecoline regulates distinct core signaling pathways in oral submucous fibrosis and oral squamous cell carcinoma
BMC Oral Health (2023)
-
A multiplex blood-based assay targeting DNA methylation in PBMCs enables early detection of breast cancer
Nature Communications (2023)